Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) have earned an average rating of “Moderate Buy” from the nine ratings firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $18.00.

A number of equities analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 target price on shares of Eupraxia Pharmaceuticals in a research note on Monday, May 4th. Wall Street Zen lowered Eupraxia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research report on Tuesday, April 21st. William Blair began coverage on Eupraxia Pharmaceuticals in a report on Monday, March 23rd. They set an “outperform” rating for the company. Finally, Oppenheimer assumed coverage on Eupraxia Pharmaceuticals in a research report on Thursday, June 25th. They issued an “outperform” rating and a $17.00 target price on the stock.

Hedge Funds Weigh In On Eupraxia Pharmaceuticals

Several hedge funds have recently made changes to their positions in EPRX. Aptus Capital Advisors LLC acquired a new stake in shares of Eupraxia Pharmaceuticals in the fourth quarter valued at approximately $76,000. Guardian Wealth Advisors LLC NC acquired a new position in Eupraxia Pharmaceuticals during the fourth quarter worth $76,000. Integrated Wealth Concepts LLC acquired a new position in Eupraxia Pharmaceuticals during the third quarter worth $71,000. Bank of America Corp DE grew its position in Eupraxia Pharmaceuticals by 402.4% in the second quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock valued at $72,000 after purchasing an additional 10,059 shares in the last quarter. Finally, Geode Capital Management LLC bought a new position in Eupraxia Pharmaceuticals in the fourth quarter valued at $105,000.

Eupraxia Pharmaceuticals Stock Performance

Shares of EPRX opened at $6.92 on Thursday. The firm has a market cap of $449.94 million, a P/E ratio of -6.59 and a beta of 1.05. Eupraxia Pharmaceuticals has a twelve month low of $4.88 and a twelve month high of $9.32. The company has a debt-to-equity ratio of 0.02, a quick ratio of 19.31 and a current ratio of 19.31. The firm’s 50 day moving average price is $6.75 and its two-hundred day moving average price is $7.43.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.01). On average, analysts forecast that Eupraxia Pharmaceuticals will post -0.88 EPS for the current fiscal year.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.